Drugs in Dev. Neurology
IND Enabling
China 
Lead Product(s) : XS411
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
XellSmart's iPSC Cell Therapies for Parkinson’s and ALS Approved for Phase I
Details : XS411 is an universal allogeneic off-the-shelf iPS-derived dopaminergic neural progenitor cell therapy being developed for the treatment of Parkinson's disease (PD).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : XS411
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JMKX000623
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Details : According to the agreement, Orion has the right to develop and commercialise the JMKX000623, NaV 1.8 blocker asset in its territory. Orion will be fully responsible for its own development and commercialisation costs.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $15.8 million
May 06, 2022
Lead Product(s) : JMKX000623
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : JMKX000623
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Details : According to the agreement, Orion has the right to develop and commercialize the drug precursor in its own territory. JMKX000623 is a potent and selective Nav1.8 blocker independently developed by Jemincare.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $16.1 million
May 06, 2022
Lead Product(s) : JMKX000623
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Orelabrutinib
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This will be a randomized, double-blind, placebo-controlled and multi-center phase II Study in Relapsing-Remitting multiple sclerosis patients (RRMS). Orelabrutinib is a highly selective BTK inhibitor targeting both B-cell lymphomas and autoimmune indica...
Product Name : Hibruka
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 02, 2020
Lead Product(s) : Orelabrutinib
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Oligomannate
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Green Valley to Start US Trials of Algae-Based Alzheimer’s Drug
Details : Green Valley Pharma’s scientists have suggested that GV-971 may work by altering the balance of microorganisms in the GI tract that contribute to inflammation in the central nervous system.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 27, 2020
Lead Product(s) : Sodium Oligomannate
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
